Kymera Therapeutics (NASDAQ: KYMR) COO logs grants and share sales

Rhea-AI Filing Summary

Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a mix of equity awards and share sales. On March 2, 2026 he received 12,575 restricted stock units that vest in three equal annual installments following March 3, 2025, plus a stock option for 25,150 shares vesting in 48 equal monthly installments following March 2, 2026. That same day he sold 2,039 common shares in open‑market transactions, including shares sold automatically to cover tax withholding on vesting RSUs. On March 4, 2026 he sold an additional 3,919 common shares in open‑market transactions at weighted average prices ranging from $83.9965 to $89.6574 per share. After these transactions he directly owned 73,810 Kymera common shares, in addition to the newly granted option award.

Insider Trade Summary

Net Seller: 5,958 shares ($515,594)

Net Sell 9 txns

Insider Chadwick Jeremy G

Role Chief Operating Officer

Sold 5,958 shs ($516K)

Type	Security	Shares	Price	Value
Sale	Common Stock	394	$83.9965	$33K
Sale	Common Stock	2,017	$85.0364	$172K
Sale	Common Stock	1,150	$85.7807	$99K
Sale	Common Stock	358	$86.6247	$31K
Grant/Award	Stock Option (Right to Buy)	25,150	$0.00	--
Grant/Award	Common Stock	12,575	$0.00	--
Sale	Common Stock	549	$87.7509	$48K
Sale	Common Stock	383	$88.5004	$34K
Sale	Common Stock	1,107	$89.6574	$99K

Holdings After Transaction: Common Stock — 77,335 shares (Direct); Stock Option (Right to Buy) — 25,150 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. This number includes 773 shares and shares acquired under the Registrant's employee stock purchase plan. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/04/2026 - 06:00 PM Learn about SEC filing dates

FAQ

What insider transactions did Kymera Therapeutics (KYMR) report for its COO?

Kymera’s COO Jeremy G. Chadwick reported both equity grants and share sales. He received 12,575 restricted stock units and a stock option for 25,150 shares, and sold a total of 5,958 common shares in open‑market transactions on March 2 and March 4, 2026.

How many Kymera Therapeutics (KYMR) shares did the COO sell and at what prices?

The COO sold 5,958 Kymera common shares in total. On March 2, 2026 he sold 2,039 shares, and on March 4, 2026 another 3,919 shares, at weighted average prices ranging from $83.9965 to $89.6574 per share in open‑market transactions.

What equity awards did the Kymera Therapeutics (KYMR) COO receive in this Form 4?

Jeremy G. Chadwick received two main equity awards. He was granted 12,575 restricted stock units vesting in three equal annual installments after March 3, 2025, and a stock option covering 25,150 shares vesting in 48 equal monthly installments after March 2, 2026.

Were any Kymera Therapeutics (KYMR) COO share sales related to tax withholding?

Yes, part of the COO’s sales were for tax withholding. A footnote states some shares were required to be sold automatically to cover tax withholding obligations arising from the vesting of restricted stock units, and these sales were not at his discretion.

How many Kymera Therapeutics (KYMR) shares does the COO hold after these transactions?

After the reported trades, the COO directly owned 73,810 Kymera common shares. In addition, he holds a newly granted stock option for 25,150 shares and restricted stock units that will vest over time, subject to continued employment conditions.

How do the Kymera Therapeutics (KYMR) COO’s RSUs vest over time?

The COO’s restricted stock units vest in three annual installments. Each of the 12,575 RSUs represents one common share, with vesting occurring in three equal annual installments following March 3, 2025, contingent on his continued employment through each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chadwick Jeremy G

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		12,575(1)	A	$0	79,768(2)	D
Common Stock	03/02/2026		S(3)		549	D	$87.7509(4)	79,219	D
Common Stock	03/02/2026		S(3)		383	D	$88.5004(5)	78,836	D
Common Stock	03/02/2026		S(3)		1,107	D	$89.6574(6)	77,729	D
Common Stock	03/04/2026		S(3)		394	D	$83.9965(7)	77,335	D
Common Stock	03/04/2026		S(3)		2,017	D	$85.0364(8)	75,318	D
Common Stock	03/04/2026		S(3)		1,150	D	$85.7807(9)	74,168	D
Common Stock	03/04/2026		S(3)		358	D	$86.6247(10)	73,810	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$90.1	03/02/2026		A		25,150		(11)	03/01/2036	Common Stock	25,150	$0	25,150	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.

2. This number includes 773 shares and shares acquired under the Registrant's employee stock purchase plan.

3. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

11. The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.